NCT06939985|Recruiting
Cardiometabolic evalUation REgistry of Heart Failure
CURE-HF
Cardiometabolic Risk Factors and Clinical Outcomes in Heart Failure: An Observational Cohort Study
Loading search results
CURE-HF
Cardiometabolic Risk Factors and Clinical Outcomes in Heart Failure: An Observational Cohort Study
Sponsor study identifier
observational
5,000
1 country
1
Study Start
January 1, 2015
Actual (reported)Primary Completion
May 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
May 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This is a combined retrospective-prospective observational cohort study investigating the role of systemic and local cardiometabolic risk factors in cardiac structural/functional remodeling and clinical outcomes among heart failure (HF) patients. The study integrates retrospective clinical data (from the past 10 years) and prospective longitudinal follow-up (5 years) of HF patients across HF with reduced (HFrEF), mildly-reduced (HFmrEF), preserved (HFpEF) and improved ejection fraction (HFimpEF) phenotypes. Systemic metabolic factors (e.g., blood lipid profiles, glycemic levels, insulin resistance) and local factors (e.g., epicardial adipose tissue \[EAT\], perivascular adipose tissue \[PVAT\]) will be analyzed for their associations with changes in cardiac geometrics and function, dynamic transitions between HF phenotypes, as well as the occurrence of major adverse cardiovascular events (MACEs). The study seeks to advance risk stratification by integrated evaluation of cardiometabolic profiles so as to refine personalized cures in HF management.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 1, 2015
Actual (reported)April 8, 2025
Actual (reported)April 23, 2025
Actual (reported)May 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
May 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Changes in cardiac function
Changes in ejection fraction (EF) measured by echocardiography or cardiac MRI at baseline and during follow-up.
12 months
Major cardiovascular events (MACEs)
A composite endpoint of HF re-hospitalizaion and cardiovascular death during follow-up
5 years
HF re-hospitalization
5 years
This is a combination of retrospective and prospective cohort. Ambulatory and hospitalized patients with chronic HF (NYHA II-IV) across all ejection fraction phenotypes are consecutively enrolled.
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, 200025, China
Blood samples
Ruiyan Zhang, M.D., Ph.D.
Ruijin Hospital
Xiaoqun Wang, M.D., Ph.D.
Ruijin Hospital
First Submitted
April 8, 2025
First Posted
April 23, 2025
Study Start
January 1, 2015
Actual (reported)Primary Completion
May 31, 2027
EstimatedCardiovascular death
5 years
All-cause mortality
5 years
Dynamic transition among HF phenotypes
12 months
Changes in cardiac diastolic function
12 months
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
May 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
April 23, 2025
Record last verified: 2025-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: